Dosimetry in a myeloablative setting

Cancer Biotherapy and Radiopharmaceuticals

Volumn 17, Issue 1, 2002, Pages 119-128

  Breitz, Hazel ^a  

^a Poniard Pharmaceuticals Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DOTMP HO 166; HOLMIUM; HOLMIUM 166; INDIUM 111; IODINE 131; LEXIDRONAM SAMARIUM SM 153; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY 170H.80 Y 90; MONOCLONAL ANTIBODY B1 I 131; MONOCLONAL ANTIBODY CC49; MONOCLONAL ANTIBODY CC49 I 131; MONOCLONAL ANTIBODY CD33 I 131; MONOCLONAL ANTIBODY CD66C RE 188; MONOCLONAL ANTIBODY MN14F(AB) I 131; MYELOABLATIVE AGENT; PHOSPHONIC ACID DERIVATIVE; RADIOISOTOPE; UNCLASSIFIED DRUG; YTTERBIUM;

ACCURACY; ACUTE GRANULOCYTIC LEUKEMIA; BONE MARROW CELL; BONE MARROW TOXICITY; CANCER; CLINICAL TRIAL; CONFERENCE PAPER; DOSIMETRY; DRUG SAFETY; DRUG TARGETING; GASTROINTESTINAL SYMPTOM; HEMATOPOIETIC SYSTEM; HUMAN; LEUKEMIA; MUCOSA INFLAMMATION; PRIORITY JOURNAL; RADIATION DOSE; STEM CELL TRANSPLANTATION; THYROID CANCER; TREATMENT PLANNING; WHOLE BODY RADIATION;

EID: 0036186564     PISSN: 10849785     EISSN: None     Source Type: Journal    
DOI: 10.1089/10849780252824136     Document Type: Conference Paper

References (32)

1. High dose cancer therapy
2. Peptide receptor imaging and therapy
3. Radiopeptide therapy with cholecystokinin (CCK)-B/Gastrin receptor ligands: Toxicity and therapeutic efficacy of auger electrons versus alpha or beta emitters
4. 90Y-DOTA-biotin with pretargeted NR-LU-10/Streptavidin
5. 166Holmium-DOTMP in combination with high dose melphalan +/- total body irradiation (TBI) with autologous stem cell transplant (ASCT)
6. Phase I high dose Samarium-153 ethylenediaminetetramethylenephosphate and melphalan therapy of multiple myeloma with peripheral blood stem cell support
7. Strategies for developing effective radioimmunotherapy for solid tumors
8. Stem cell responses after radiation exposure: A key to the evaluation and prediction of its effects
9. Radiolabeled-antibody therapy of B-cell lymphoma with autologous bone marrow support
10. Dosimetry based therapy in metastatic breast cancer patients using Y-90 Mab 170H.82 with autologous stem cell support and cyclosporin A
11. 90Y Mx diethylenetriaminepentaacetic acid (DTPA)-BrE-3 and autologous hematopoietic stem cell support (AHSCS) for the treatment of advanced breast cancer: A phase I trial
12. 186Rhenium MAG2GABA Antibody radiolabeling for high dose radioimmunotherapy studies
13. High-dose therapy with iodine-131-labeled monoclonal antibody CC49 in patients with gastrointestinal cancers: A phase I trial
14. Radioimmunotherapy for breast cancer using escalating fractionated doses of 131I labeled chimeric L6 antibody with peripheral blood progenitor cell transfusions
15. Initial results of a phase I trial evaluating yttrium-90 chimeric T84.66 anti-CEA antibody and autologous stem cell support in CEA-producing metastatic breast cancer
16. 90Y monoclonal antibody 170H.82 with autologous stem cell support and cyclosporin A
17. Combined modality radiation using radioimmunotherapy and external beam radiation for breast and prostate cancer
18. Initial experience with high dose radioimmunotherapy of medullary thyroid carcinoma using 131-I-MN-14 F(ab)2 anti-carcinoembryonic antigen (CEA) monoclonal antibody and autologous hematopoeitic stem rescue
19. Current uses of monoclonal antibodies in the treatment of acute leukemia
20. A phase I trial of monoclonal antibody M195 in acute myelogenous leukemia. Specific bone marrow targeting and internalization of radionuclide
21. The use of radiolabeled anti-CD33 antibody to augment marrow irradiation prior to marrow transplantation for acute myelogenous leukemia
22. Potential for myeloablation with yttrium-90-labeled HuM195 (anti-CD33): A phase I trial in advanced myeloid leukemias
23. Phase I trial of targeted alpha-particle therapy for myeloid leukemias with bismuth-213-HuM195
24. Phase I study of 131I-anti-CD45 antibody cyclophosphamide and total body irradiation for advanced acute myeloid leukemia and myelodysplastic syndrome
25. Results of a phase I-II study of radioimmunotherapy for the intensification of conditioning prior to stem cell transplantation for patients with high-risk haematological malignancies
26. Tolerance of normal tissue to therapeutic irradiation
27. MIRD Pamphlet No. 14, revised - A dynamic urinary bladder model for radiation dose calculations
28. A preliminary phantom study on a proposed model for quantification of renal planar scintigraphy
29. Practical determination of organ S-values for individual patients for therapy